Nicox SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR0013018124
EUR
0.29
-0.01 (-2.5%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Nicox SA stock-summary
stock-summary
Nicox SA
Pharmaceuticals & Biotechnology
Nicox SA is a France-based international ophthalmic company. It is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients. Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The Company has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis). It has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets.
Company Coordinates stock-summary
Company Details
Drakkar 2 - Batiment D, 2405 route des Dolines, CS 10313 Sophia Antipolis, VALBONNE None : 06560
stock-summary
Tel: 33 4 97245300
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Michele Garufi
Chairman of the Board and Chief Executive Officer, Member of the Management Committee
Dr. Adrienne Graves
Non-Executive Independent Director
Dr. Lester Kaplan
Non-Executive Independent Director
Mr. Jean-Francois Labbe
Non-Executive Independent Director
Mrs. Lauren Silvernail
Non-Executive Independent Director
Mrs. Birgit Stattin Norinder
Non-Executive Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
4 Million
(Quarterly Results - Sep 2017)
Net Profit:
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 25 Million ()

stock-summary
P/E

0

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.45

stock-summary
Return on Equity

0.00%

stock-summary
Price to Book

-4.00